Name | (6aS,13bR)-11-Chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepin-12-ol hydrobromide (1:1) |
---|---|
Synonyms |
5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, (6aS,13bR)-, hydrobromide (1:1)
(6aS,13bR)-11-Chloro-7-methyl-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphtho[2,1-b]azepin-12-ol hydrobromide (1:1) SCH39166 |
Description | SCH 39166 hydrobromide (SCH391660) is potent and selective antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. SCH 39166 hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). SCH 39166 hydrobromide can be used for the research of schizophrenia, cocaine addition, and obesity[1]. |
---|---|
Related Catalog | |
Target |
D1 Receptor:1.2 nM (Ki) D5 Receptor:2.0 nM (Ki) D2 Receptor:980 nM (Ki) D4 Receptor:5520 nM (Ki) 5-HT Receptor:80 nM (Ki) Alpha-2A adrenergic receptor:731 nM (Ki) |
In Vitro | SCH 39166 (2 μM) hydrobromide completely abolishes the proconvulsive effect of Dopamine (10 μM) in isolated corticohippocampal formation[2]. |
In Vivo | SCH 39166 (0.003-0.3 mg/kg; a single s.c.) hydrobromide abolishes Nicotine-induced enhancement of a sensory reinforcer in adult rats[3]. Animal Model: Male young adult Long-Evans rats were injected with Nicotine[3] Dosage: 0.003, 0.01, 0.03, 0.1, 0.3 mg/kg Administration: A single s.c. 20 min before Nicotine (0.1 mg/kg) Result: Dose-dependently reduced pressing on both active and inactive levers. |
References |
Molecular Formula | C19H21BrClNO |
---|---|
Molecular Weight | 394.73 |
Exact Mass | 393.049500 |